Administration Can’t Be Trusted With Generic User Fees, Rep. Waxman Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Rep. Henry Waxman (D-Calif.) is opposing possible user fees for generic drug applications, arguing that the societal benefit of rapid generic entry justifies increased appropriations for the office
You may also be interested in...
First Generic User Fees Proposed By Deputy Commissioner Gottlieb
GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.